{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:18:43Z","timestamp":1773098323988,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.coi.2023.102374","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T14:11:06Z","timestamp":1691503866000},"page":"102374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["An easy pill to swallow: oral recombinant vaccines for the 21st century"],"prefix":"10.1016","volume":"84","author":[{"given":"Molly R","family":"Braun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becca A","family":"Flitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean N","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2023.102374_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2005.12.003","article-title":"Needle-free vaccine delivery","volume":"58","author":"Giudice","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.coi.2023.102374_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2017.04.008","article-title":"Current state and challenges in developing oral vaccines","volume":"114","author":"Vela Ramirez","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.coi.2023.102374_bib3","unstructured":"The Coalition for Epidemic Preparedness Innovations 2023. Available from: \u3008https:\/\/100days.cepi.net\/\u3009."},{"issue":"4","key":"10.1016\/j.coi.2023.102374_bib4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3201\/eid2004.130725","article-title":"Efficiency of points of dispensing for influenza A(H1N1)pdm09 vaccination, Los Angeles County, California, USA, 2009","volume":"20","author":"Saha","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coi.2023.102374_bib5","series-title":"CNBC","article-title":"U.S. reaches 70% Covid vaccine milestone for adults about a month behind Biden\u2019s goal","author":"Lovelace","year":"2021"},{"key":"10.1016\/j.coi.2023.102374_bib6","unstructured":"Centers for Disease Control. Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations. 2022. Available online: https:\/\/www.cdc.gov\/vaccines\/hcp\/admin\/mass-clinic-activities\/index.html#print."},{"key":"10.1016\/j.coi.2023.102374_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/d41591-022-00053-9","article-title":"Six places where drones are delivering medicines","volume":"28","author":"Snouffer","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2023.102374_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085582","article-title":"Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity","volume":"9","author":"Muramatsu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2023.102374_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007427","article-title":"IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody","volume":"15","author":"Saito","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2023.102374_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107148118","article-title":"Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG","volume":"118","author":"Sun","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2023.102374_bib11","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1074\/jbc.M807529200","article-title":"The nonplanar secretory IgA2 and near planar secretory IgA1 solution structures rationalize their different mucosal immune responses","volume":"284","author":"Bonner","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2023.102374_bib12","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1074\/jbc.M112.410811","article-title":"Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies","volume":"288","author":"Longet","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2023.102374_bib13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1172\/JCI119286","article-title":"Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses","volume":"99","author":"Quiding-Jarbrink","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2023.102374_bib14","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.1016\/j.vaccine.2012.09.018","article-title":"The role of nasal IgA in children vaccinated with live attenuated influenza vaccine","volume":"30","author":"Ambrose","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2023.102374_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146010","article-title":"Human circulating antibody-producing b cell as a predictive measure of mucosal immunity to poliovirus","volume":"11","author":"Dey","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2023.102374_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004753","article-title":"Antibody secreting cell responses following vaccination with bivalent oral cholera vaccine among Haitian adults","volume":"10","author":"Matias","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coi.2023.102374_sbref15","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10040593","article-title":"Drop the needle; a temperature stable oral tablet vaccine is protective against respiratory viral pathogens","volume":"10","author":"Flitter","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.coi.2023.102374_bib18","series-title":"Healthcare Lessons From A Pandemic: A Place for Glass Alternatives","author":"Ganti","year":"2022"},{"key":"10.1016\/j.coi.2023.102374_sbref17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2023.102374_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2023.102374_sbref19","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.chom.2021.10.009","article-title":"Human influenza virus challenge identifies cellular correlates of protection for oral vaccination","volume":"29","author":"McIlwain","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coi.2023.102374_bib22","first-page":"1","article-title":"SARS-CoV-2 oral tablet vaccination induces neutralizing mucosal IgA in a phase 1 open label trial","author":"Johnson","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.coi.2023.102374_bib23","article-title":"Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2023.102374_bib24","unstructured":"Vaxart Inc.\u201cVaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill V\u00a0accine Candidate\u201d 2022.https:\/\/investors.vaxart.com\/news-releases\/news-release-details\/vaxart-announces-positive-top-line-phase-ii-clinical-study-data."},{"key":"10.1016\/j.coi.2023.102374_bib25","series-title":"Potent Immune Responses to Norovirus G1.1 Evaluated in Elderly Subjects following Oral Tablet Delivery in a Phase 1 Placebo-Controlled Study","author":"Cummings","year":"2022"},{"key":"10.1016\/j.coi.2023.102374_bib26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/infdis\/jiz540","article-title":"Production and clinical evaluation of Norwalk GI.1 virus lot 001-09NV in norovirus vaccine development","volume":"221","author":"Mateo","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2023.102374_sbref24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121077","article-title":"Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial","volume":"3","author":"Kim","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2023.102374_bib28","first-page":"1","article-title":"Adenoviral-based vaccine elicits robust systemic and mucosal cross-reactive responses in African green monkeys and reduces shedding after SARS-CoV-2 challenge","author":"Tedjakusuma","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.coi.2023.102374_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/CVI.00552-12","article-title":"An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models","volume":"20","author":"Scallan","year":"2013","journal-title":"Clin Vaccin Immunol"},{"key":"10.1016\/j.coi.2023.102374_bib30","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.vaccine.2019.04.069","article-title":"An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling","volume":"37","author":"Dora","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2023.102374_bib31","first-page":"1","article-title":"Mucosal immunization of cynomolgus macaques with adenoviral vector vaccine elicits neutralizing nasal and serum antibody to several SARS-CoV-2 variants","author":"Flitter","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.coi.2023.102374_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1086035","article-title":"Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2","volume":"14","author":"Braun","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102374_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/infdis\/jiab561","article-title":"Oral vaccination protects against severe acute respiratory syndrome coronavirus 2 in a Syrian hamster challenge model","volume":"225","author":"Johnson","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2023.102374_bib34","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1016\/j.vaccine.2018.05.112","article-title":"Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats","volume":"36","author":"Joyce","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2023.102374_sbref32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn6868","article-title":"Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model","volume":"14","author":"Langel","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2023.102374_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151219","article-title":"Global economic burden of norovirus gastroenteritis","volume":"11","author":"Bartsch","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2023.102374_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005334","article-title":"Correlates of protection against norovirus infection and disease-where are we now, where do we go?","volume":"12","author":"Ramani","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2023.102374_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1521-6616(03)00120-7","article-title":"Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers","volume":"108","author":"Tacket","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2023.102374_bib39","unstructured":"Tucker, S., et al.: Oral vaccine to prevent norovirus infection induces mucosal homing plasmablasts and T follicular cells in humans (and bivalent phase I data). In The 7th International Calicivirus Meeting. 2019. Sydney, Australia."},{"key":"10.1016\/j.coi.2023.102374_bib40","unstructured":"Vaxart Inc.,Vaxart announces collaborative funding from leading foundation to study its norovirus vaccine candidate in breastfeeding mothers 2022 South San Francisco, California.https:\/\/investors.vaxart.com\/news-releases\/news-release-details\/vaxart-announces-collaborative-funding-leading-foundation-study."},{"key":"10.1016\/j.coi.2023.102374_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100561","article-title":"Norovirus-specific immunoglobulin A in breast milk for protection against norovirus-associated diarrhea among infants","volume":"27","author":"Labayo","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.coi.2023.102374_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0168-1656(95)00105-0","article-title":"Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization","volume":"44","author":"Avtushenko","year":"1996","journal-title":"J Biotechnol"},{"key":"10.1016\/j.coi.2023.102374_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2023.102374_bib44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2023.102374_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1473-3099(22)00816-7","article-title":"Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2023.102374_bib46","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coi.2023.102374_sbref42","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMc2209651","article-title":"Anti-spike mucosal IgA protection against SARS-CoV-2 Omicron infection","volume":"387","author":"Havervall","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2023.102374_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2023.102374_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104298","article-title":"Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial","volume":"85","author":"Madhavan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coi.2023.102374_bib50","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2023.102374_bib51","series-title":"Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities","article-title":"Convidecia Air: an alternative way to fight against COVID-19","author":"Chao","year":"2022"},{"key":"10.1016\/j.coi.2023.102374_bib52","series-title":"Oral Tablet Vaccination to SARS-CoV-2 Induces Long Lasting Cross-reactive Mucosal Antibody Responses in Humans","author":"Tucker","year":"2022"},{"key":"10.1016\/j.coi.2023.102374_bib53","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1056\/NEJMoa055414","article-title":"Effectiveness of school-based influenza vaccination","volume":"355","author":"King","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2023.102374_bib54","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1128\/JVI.00979-13","article-title":"Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs","volume":"87","author":"Seibert","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102374_bib55","unstructured":"QuadrantSolutions, \"Opinions and Attitudes on COVID-19 Vaccine Pill\" 2021, Available online: https:\/\/investors.vaxart.com\/static-files\/cbf26eda-2ffa-4cb2-b031\u20130cb9b02fedac."},{"key":"10.1016\/j.coi.2023.102374_bib56","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.11.04004","article-title":"How the use of vaccines outside the cold chain or in controlled temperature chain contributes to improving immunization coverage in low- and middle-income countries (LMICs): a scoping review of the literature","volume":"11","author":"Dadari","year":"2021","journal-title":"J Glob Health"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791523000936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791523000936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:50:11Z","timestamp":1760604611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791523000936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":56,"alternative-id":["S0952791523000936"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2023.102374","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An easy pill to swallow: oral recombinant vaccines for the 21st century","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2023.102374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102374"}}